Mary Margaret Mullen

This study uses single-cell transcriptomics on patient-derived organoids to identify AGRIN as a regulator of metastatic competence in high-grade serous ovarian cancer.

This paper introduces 3D printed bioelectronic scaffolds for impedance-based cytotoxicity monitoring in 3D cancer cell cultures, demonstrating their effectiveness in drug response assessment.

This study shows that targeting ALC1 can enhance PARP inhibitor effectiveness in ovarian cancers, particularly in HRD and CCNE1-amplified tumors, with minimal toxicity.

This study identifies RAD52 as a target to overcome PARP inhibitor resistance in BRCA2-deficient ovarian cancer by showing its role in DNA repair and demonstrating synergistic effects with PARP inhibitors.

The paper identifies COPS5 as a therapeutic target for overcoming platinum resistance in ovarian cancer by inhibiting nucleotide excision repair and interstrand crosslink repair.

This study identifies phospho-RPA2 as a biomarker predicting response to platinum and PARP inhibitors in HR-proficient ovarian cancer, showing higher pathologic complete response and longer survival in pRPA2-High tumors.

This study shows APOBEC3A promotes ovarian cancer metastasis by altering epithelial-to-mesenchymal transition in high-grade serous ovarian cancer.

The paper uses single nuclei RNA sequencing to identify replication stress and DNA damage response in adrenocortical carcinoma, suggesting ATR as a potential therapeutic target.

This study shows cholestasis shifts hepatic Tregs to a Th17 phenotype and impairs their suppressor function, with bile acid levels influencing Treg activity and liver injury.